259 East Grand Avenue
South San Francisco
Freenome (free•nohm) is the dynamic collection of genetic material floating in your blood (cell-free) derived from the trillions of cells in your body. It is your living cell-free genome changing over time and space.
Founder and CEO: Gabriel Otte
Founder and COO: Riley Ennis
CTO: Michael Otte
CBO: Adam Drake
11 articles with Freenome
Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests
Freenome announced the creation of its IMPACT Advisory Board, a group tasked with helping Freenome’s leadership team optimize the company’s short- and long-term strategies, including those for its first commercial launch.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
QIAGEN N.V. announced a partnership with Freenome, a leading artificial intelligence (AI) genomics company, to accelerate the development and commercialization of next-generation sequencing (NGS) tests to enable precision medicine in cancer treatment.
Freenome’s platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies.
1/8/2018Freenome, headquartered in South San Francisco, is focused on developing a diagnostic test for early detection of cancer and other diseases on the so-called "liquid biopsy," in other words, blood.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
For nearly three decades, Dr. Scott has been an entrepreneur and visionary leader in genomic medicine.
Freenome announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in genomics and machine learning.